期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 63, 期 23, 页码 2503-2509出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2014.03.031
关键词
acute coronary syndrome(s); adenosine; antiplatelet agents; P2Y12; ticagrelor
This review constitutes a critical evaluation of recent publications that have described an additional mode of action of the P2Y(12) receptor antagonist ticagrelor. The effect is mediated by inhibition of the adenosine transporter ENT1 (type 1 equilibrative nucleoside transporter), which provides protection for adenosine from intracellular metabolism, thus increasing its concentration and biological activity, particularly at sites of ischemia and tissue injury where it is formed. Understanding the mode of action of ticagrelor is of particular interest given that its clinical profile, both in terms of efficacy and adverse events, differs from that of thienopyridine P2Y(12) antagonists. (c) 2014 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据